Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 1/20 | 0.52 |
| ▸ | IDO1 | P14902 | 4/20 | 0.52 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.50 |
| ▸ | APP | P05067 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | CA12 | O43570 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | CA7 | P43166 | 1/20 | 0.46 |
| ▸ | CA9 | Q16790 | 1/20 | 0.46 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.46 |
| ▸ | AGXT | P21549 | 1/20 | 0.45 |
| ▸ | LTA4H | P09960 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12510871 | 0.84 | EPHX1 (0.44) | SLC6A4IDO1EPHX1ALDH1A1SMN1; SMN2 | |
| SCHEMBL7088679 | 0.84 | SLC6A4 (0.58) | SLC6A4IDO1EPHX1APPALDH1A1 | |
| SCHEMBL21787935 | 0.82 | CYP1A2 (0.57) | ALDH1A1CYP3A4GAA | |
| SCHEMBL21788136 | 0.80 | CYP2C19 (0.56) | ALDH1A1TSHRSMN1; SMN2L3MBTL1LTA4H | |
| SCHEMBL8932525 | 0.79 | IDO1 (0.51) | SLC6A4IDO1EPHX1APPALDH1A1 | |
| SCHEMBL7881281 | 0.79 | SLC6A4 (0.52) | SLC6A4IDO1EPHX1APPALDH1A1 | |
| SCHEMBL7346371 | 0.78 | L3MBTL1 (0.62) | IDO1EPHX1ALDH1A1TP53SMN1; SMN2 | |
| SCHEMBL62037 | 0.78 | IDO1 (0.59) | SLC6A4IDO1APPALDH1A1TP53 | |
| SCHEMBL769511 | 0.78 | IDO1 (0.59) | SLC6A4IDO1APPALDH1A1TP53 | |
| SCHEMBL12125567 | 0.77 | TAAR1 (0.59) | IDO1TP53SMN1; SMN2AGXTTAAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1089963-B1 | HYDROXAMIC ACID DERIVATIVES AS INHIBITORS OF THE PRODUCTION OF HUMAN CD23 AND OF THE TNF RELEASE | SMITHKLINE BEECHAM PLC (GB) | 2004-06-16 | — | — | EP | claimed |
| EP-0905126-B1 | Metalloproteinase inhibitors | BRITISH BIOTECH PHARM (GB) | 2002-12-04 | — | — | EP | claimed |
| US-6458779-B1 | TREATMENT OF CONDITIONS ASSOCIATED WITH EXCESS PRODUCTION OF SOLUBLE CD23 (S-CD23) SUCH AS AUTOIMMUNE DISEASE AND ALLERGY. THE COMPOUNDS OF THE INVENTION ARE ALSO INHIBITORS OF THE RELEASE OF TUMOUR NECROSIS FACTOR (TNF). | SMITHKLINE BEECHAM P.L.C. (GB) | 2002-10-01 | — | — | US | claimed |
| EP-0740655-B1 | METALLOPROTEINASE INHIBITORS | BRITISH BIOTECH PHARM (GB) | 1999-10-20 | — | — | EP | claimed |
| US-5902791-A | TREATING RHEUMATOID ARTHRITIS, OSTEOARTHRITIS, PERIODONTAL DISEASE, GINGIVITIS, CORNEAL ULCERATION OR TUMOR METASTASES | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 1999-05-11 | — | — | US | claimed |
| EP-0905126-A1 | Metalloproteinase inhibitors | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 1999-03-31 | — | — | EP | claimed |
| EP-0740655-A1 | METALLOPROTEINASE INHIBITORS | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 1996-11-06 | — | — | EP | claimed |
| WO-1995019961-A1 | METALLOPROTEINASE INHIBITORS | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 1995-07-27 | — | — | WO | claimed |
| EP-3934757-B1 | 2'3'-CYCLIC DINUCLEOTIDES AND PRODRUGS THEREOF | INST OF ORGANIC CHEMISTRY AND BIOCHEMISTRY ASCR V V I (CZ) | 2023-02-22 | — | — | EP | disclosed |
| US-9185909-B2 | Synthesis of resveratrol-based natural products | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2015-11-17 | — | — | US | disclosed |
| US-8883828-B2 | 2-aminopyridine analogs as glucokinase activators | ARRAY BIOPHARMA INC. (US) | 2014-11-11 | — | — | US | disclosed |
| EP-2687516-A1 | Inhibitors of C-FMS Kinase | Janssen Pharmaceutica N.V. (BE) | 2014-01-22 | — | — | EP | disclosed |
| US-20130065901-A1 | 2-AMINOPYRIDINE ANALOGS AS GLUCOKINASE ACTIVATORS | ARRAY BIOPHARMA INC. (US) | 2013-03-14 | — | — | US | disclosed |
| US-8354540-B2 | 2-aminopyridine analogs as glucokinase activators | ARRAY BIOPHARMA INC. (US) | 2013-01-15 | — | — | US | disclosed |
| US-6017889-A | Metalloproteinase inhibitors | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 2000-01-25 | — | — | US | disclosed |
| EP-0740655-B1 | METALLOPROTEINASE INHIBITORS | BRITISH BIOTECH PHARM (GB) | 1999-10-20 | — | — | EP | disclosed |
| US-5902791-A | TREATING RHEUMATOID ARTHRITIS, OSTEOARTHRITIS, PERIODONTAL DISEASE, GINGIVITIS, CORNEAL ULCERATION OR TUMOR METASTASES | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 1999-05-11 | — | — | US | disclosed |
| EP-0905126-A1 | Metalloproteinase inhibitors | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 1999-03-31 | — | — | EP | disclosed |
| EP-0740655-A1 | METALLOPROTEINASE INHIBITORS | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 1996-11-06 | — | — | EP | disclosed |
| WO-1995019961-A1 | METALLOPROTEINASE INHIBITORS | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 1995-07-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130065901-A1 | 2-AMINOPYRIDINE ANALOGS AS GLUCOKINASE ACTIVATORS | GCK, GCKR, GALK1 | SLC6A4 2031/4885IDO1 2695/4885EPHX1 4374/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.